Results 1 to 10 of about 10,664 (186)

Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study [PDF]

International Journal of Infectious Diseases, 2021
Objectives: Canakinumab is an IL-1β antibody that neutralises the activity of IL-1β. This study examined the efficacy and safety of canakinumab in patients with moderate COVID-19-related pneumonia.
Daniele Generali, Laura Romanini, Luca Pianta   +2 more
exaly   +6 more sources

Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases

The Turkish Journal of Pediatrics, 2020
Background and Objectives. The aim of this observational retrospective cohort study was to demonstrate indications and response rates of the patients with pediatric rheumatic diseases that used canakinumab. Method. The files of the patients
Mustafa Çakan, Şerife Gül Karadağ, Nuray Aktay Ayaz   +2 more
doaj   +3 more sources

Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever

Rheumatology, 2023
OBJECTIVES: There is no consensus on canakinumab treatment tapering and discontinuation strategies in colchicine-resistant FMF patients. In this study, we aimed to establish a treatment management and discontinuation protocol in paediatric FMF patients ...
Seher Sener, Veysel Cam, Ezgi Deniz Batu   +2 more
exaly   +2 more sources

Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis [PDF]

Frontiers in Pediatrics, 2022
ObjectiveMacrophage activation syndrome (MAS) is a life-threatening, potentially fatal condition associated with systemic juvenile idiopathic arthritis (sJIA). Interleukin-1 (IL-1) is a key cytokine in the pathogenesis of sJIA MAS.
Mikhail M. Kostik, Eugenia A. Isupova, Konstantin Belozerov, Tatyana S. Likhacheva, Evgeny N. Suspitsin, Evgeny N. Suspitsin, Evgeny N. Suspitsin, Rinat Raupov, Vera V. Masalova, Irina A. Chikova, Margarita F. Dubko, Olga V. Kalashnikova, Vyacheslav G. Chasnyk, Randy Q. Cron   +13 more
doaj   +2 more sources

Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases

Frontiers in Pediatrics, 2021
Anti-interleukin 1 agents are used successfully in colchicine-resistant or intolerant Familial Mediterranean Fever (FMF) patients. Sixty-five patients with FMF who received canakinumab treatment for at least 6 months due to colchicine resistance or ...
Burcu Bozkaya Yücel
exaly   +3 more sources

Canakinumab in patients with COVID-19 and type 2 diabetes – A multicentre, randomised, double-blind, placebo-controlled trial [PDF]

EClinicalMedicine, 2022
Summary: Background: Patients with type 2 diabetes and obesity have chronic activation of the innate immune system possibly contributing to the higher risk of hyperinflammatory response to SARS-CoV2 and severe COVID-19 observed in this population.
Matthias Hepprich, Jonathan M. Mudry, Claudia Gregoriano, Francois R. Jornayvaz, Sebastian Carballo, Anne Wojtusciszyn, Pierre-Alexandre Bart, Jean-Daniel Chiche, Stefan Fischli, Thomas Baumgartner, Claudia Cavelti-Weder, Dominique L. Braun, Huldrych F. Günthard, Felix Beuschlein, Anna Conen, Emily West, Egon Isenring, Stefan Zechmann, Gabriela Bucklar, Yoann Aubry, Ludovic Dey, Beat Müller, Patrick Hunziker, Philipp Schütz, Marco Cattaneo, Marc Y. Donath   +25 more
doaj   +2 more sources

Cost-Effectiveness of Canakinumab From a Canadian Perspective for Recurrent Cardiovascular Events [PDF]

CJC Open, 2022
Background: Cardiovascular (CV) disease is a condition with high levels of morbidity and mortality. Canakinumab is a novel monoclonal antibody therapy that has been shown to reduce CV events but is associated with side effects and high cost.
Kevin E. Boczar, MD, Rob Beanlands, MD, George Wells, PhD, Doug Coyle, PhD   +3 more
doaj   +2 more sources

Effectiveness of Canakinumab for First‐Line Steroid‐Free Treatment in Systemic‐Onset Juvenile Idiopathic Arthritis and Juvenile Still Disease [PDF]

ACR Open Rheumatology
Objective This prospective study assesses the response to canakinumab monotherapy administered as three monthly subcutaneous injections in glucocorticoid‐naïve patients with newly diagnosed systemic juvenile idiopathic arthritis (sJIA) and Still disease ...
Gerd Horneff, Tilman Kallinich, Markus Hufnagel, Kirsten Minden, Frank Weller‐Heinemann, Ralf Trauzeddel, Dirk Foell, Claas Hinze, Fabienne Staubi, Ariane Klein   +9 more
doaj   +2 more sources

Long-term safety of canakinumab in patients with systemic juvenile idiopathic arthritis: 5-year results from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry [PDF]

Pediatric Rheumatology Online Journal
Background Systemic juvenile idiopathic arthritis (SJIA) is a severe form of juvenile idiopathic arthritis characterized by fever, rash, chronic arthritis, and systemic inflammation.
Colleen Correll, Alis Burciu, Amita Bansal, Anne Dennos, Deepak Narayanswamy, Elodie Aubrun, Laura E. Schanberg, Li Yuhan, Rahel Schneider, Stephen Balevic, Yukiko Kimura, Timothy Beukelman, for the CARRA Registry investigators   +12 more
doaj   +2 more sources

Long-term Effectiveness and Safety of Canakinumab in Patients with TRAPS: Analysis of the RELIANCE Non-Interventional Study [PDF]

Rheumatology and Therapy
Introduction This is an interim analysis of the long-term effectiveness and safety of canakinumab in the tumor necrosis factor receptor-associated periodic syndrome (TRAPS) cohort of the RELIANCE non-interventional study.
Norbert Blank, Catharina Schuetz, Markus Hufnagel, Gerd Horneff, Michael Borte, Tilmann Kallinich, Prasad T. Oommen, Ales Janda, Joerg Henes, Julia Weber-Arden, Michael Stock, Jasmin B. Kuemmerle-Deschner   +11 more
doaj   +2 more sources